Accessibility Menu
HeartSciences logo

HeartSciences(NASDAQ) HSCS

Market Cap$7.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-99%
5 YearN/A
1 Year-43%
1 Month-26%
$2.02
+1.00%
+0.02Today
HeartSciences last closing stock price
MetricPriceDate
Last closeUSD 2.022026-08-07
HeartSciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.34%USD 2.182026-07-31
1 month-26.01%USD 2.732026-07-08
3 month+4.66%USD 1.932026-05-08
Year to date-34.63%USD 3.092025-12-31
1 year-42.94%USD 3.542025-08-07
3 year-97.94%USD 97.872023-08-08
Since inception-98.81%USD 170.002022-06-15

HeartSciences Financials at a Glance

Market Cap

$7.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.32K

Net Income (TTM)

-$9.14M

EPS (TTM)

-$3.91

P/E Ratio

-0.52

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$2.02

Volume

170,150

Open

$2.02

Previous Close

$2.02

Daily Range

$1.99 - $2.16

52-Week Range

$1.63 - $3.93

Estimated Earnings Date

Sep 10, 2026

HSCS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About HeartSciences

HeartSciences uses artificial intelligence to help doctors detect heart problems earlier. Its main products analyze heart signals to find issues traditional tests may miss. These tools aim to support healthcare providers in diagnosing heart disease more efficiently.

Gadgets and Gizmos: What HeartSciences Sells

  • MyoVista wavECG Device: A 12-lead heart signal test device with AI to spot heart dysfunction; targets clinics and hospitals. (primary source of device revenue)
  • MyoVista Insights Cloud Platform: A web-based system hosting AI tools for heart analysis, compatible with many existing devices; used by healthcare providers.
  • AI-ECG Algorithms: Software that helps detect heart relaxation issues and other cardiac problems; licensed to partners and used in research.
  • Collaborative AI Tools: Access to additional heart analysis algorithms through partnerships with universities and hospitals.

Growth Spurts and Strategic Moves

  • Launched MyoVista Insights Cloud Platform Phase 1 in 2025 to expand digital offerings.
  • Formed multi-year partnerships with Mount Sinai (in 2023) and Rutgers University (in 2022) for AI algorithm development.
  • Secured FDA "Breakthrough Device" status for a heart valve disease algorithm in 2025.
  • Raised $5.4 million through Series D Preferred Stock and expanded equity facilities in 2025.
  • Changed company name from Heart Test Laboratories to HeartSciences in October 2024.

Why HeartSciences Stands Out (Without a Stethoscope)

HeartSciences focuses on making heart tests smarter by using artificial intelligence. Its cloud platform works with many existing devices, aiming for broad adoption. Strategic partnerships help the company access new technology and speed up product development.

Five Things You Need to Know

  • Revenue was $1,900 in QQ1 2026, up from $0 in QQ1 2025.
  • Net loss was $2.05 million in QQ1 2026, flat year-over-year.
  • Operating expenses fell 10% to $1.88 million in QQ1 2026.
  • Cash and cash equivalents were $2.79 million as of July 31, 2025.
  • Company has 15 employees and operates as a single business segment.

Bottom Line

HeartSciences is a small, early-stage company using AI to improve heart diagnostics. It faces financial challenges but continues to develop new technology and partnerships.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

14

CEO

Andrew Christopher Simpson

Website

www.heartsciences.com

Headquarters

Southlake, TX 76092, US

HSCS Financials

Key Financial Metrics (TTM)

Gross Margin

-2982.10%

Operating Margin

-194787.38%

Net Income Margin

-211666.47%

Return on Equity

-358.44%

Return on Capital

-0.20%

Return on Assets

-173.71%

Earnings Yield

-1.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.90M

Volume

170.15K

Avg. Volume

2.27M

Financials (TTM)

Gross Profit

-$128.80K

Operating Income

-$8.41M

EBITDA

-$8.41M

Operating Cash Flow

-$7.43M

Capital Expenditure

-$44.45K

Free Cash Flow

-$7.47M

Cash & ST Invst.

$1.66B

Total Debt

$3.94M

HeartSciences Performance Analysis

HeartSciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-04-30USD 5,150-64.2%
20242024-04-30USD 18,600261.2%
20252025-04-30USD 4,350-76.6%
20262026-04-30USD 4,319-0.7%
HeartSciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-31-56.3%
Q22025-10-3127.3%
Q42025-12-31N/A
Q32026-01-31-100.0%
HeartSciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-04-30USD -79.924400.2%
20242024-04-30USD -18.74-76.6%
20252025-04-30USD -9.34-50.1%
20262026-04-30USD -3.48-62.7%
HeartSciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-07-3116.0%
Q22025-10-3146.2%
Q42025-12-31-36.5%
Q32026-01-3125.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$33.24K

-15.4%

Gross Margin

0.00%

N/A

Market Cap

$7.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$562.64K

N/A

Employees

14

N/A

Net Income

-$1.99M

+5.2%

EBITDA

-$1.90M

-0.3%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$1.66B

+150780.3%

Total Debt

$3.94M

+31.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$655.63M

+100724.6%

Long Term Debt

$175.50K

-44.2%

Short Term Debt

$3.76M

+40.8%

Return on Assets

-1.74%

N/A

Return on Invested Capital

-20.95%

N/A

Free Cash Flow

-$1.49M

+6.8%

Operating Cash Flow

-$1.46M

+8.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCLIBrainstorm Cell Therapeutics Inc.
$0.79-1.25%
AMIXAutonomix Medical, Inc.
$10.04-17.50%
BMRABiomerica, Inc.
$1.61+1.26%
MYNZMainz Biomed B.V.
$3.59+0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About HSCS

What is the current price of HeartSciences?

HeartSciences is trading at $2.02 per share.

What is the 52-week range for HeartSciences?

Over the past 52 weeks, HeartSciences has traded between $1.63 and $3.93.

How much debt does HeartSciences have?

As of the most recent reporting period, HeartSciences reported total debt of $3.94M.

How much cash does HeartSciences have on hand?

HeartSciences reported $1.66M in cash and cash equivalents in its most recent financial results.

What is HeartSciences’s dividend yield?

HeartSciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services